This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

October 27-29, 2020
★ VIRTUAL EVENT,
Presented in Eastern Standard Time (EST)

ENSURE CMC, REGULATORY SUCCESS AND EXPEDITED PRODUCT APPROVAL BY STREAMLINING AND OPTIMIZING CHARACTERIZATION, QUALITY AND ROBUST ASSAY DEVELOPMENT

Gain Practical Advice From Case Studies, FDA & Regulatory Leaders to Accelerate Your Biologics & Novel Modalities/Molecules to Market

WELL CHARACTERIZED BIOLOGICS & BIOLOGICAL ASSAYS IS GOING 100% DIGITAL FOR 2020

In light of the current global climate, we have made the decision to go 100% digital for this year's meeting. We're committed to providing the same top-notch networking, high-level industry expert speakers, innovative company presentations, interactive scientific poster presentations, and diverse attendee companies and investors as always—in a multi-day digital format that you can access from anywhere in the world. 

Experience the WCB 2020 Virtual Platform


It is more important than ever for the bioanalytical and regulatory community to connect with one another, share practical advice, and find new analytical or bioassay technology applications — All in a safe, responsible way.

Through our fully interactive and sophisticated virtual platform, you will be able to take advantage of this extended time to engage with people who matter to your business, be inspired by thought leaders who are making an impact and evolve together as we emerge from this crisis.

To see how a virtual conference will operate, watch our short demo for more information.

Leading Experts in the Analytical Field Share Best Practices

The speakers at WCB 2020 share practical advice from multiple case studies to apply to your own projects, and accelerate your molecule development by finding new analytical or bioassay technology applications.

Accelerate your product timelimes and overcome development and submission challenges

The 2020 program kicks off with a full day of pre-conference workshops allowing attendees to discuss their specific challenges in a expert-led classroom style setting. The main conference program then covers two main tracks, each featuring case studies with practical advice you can apply in your CMC programs and new data and lessons learned all within an open information-sharing environment.  


Well Characterized Biologics Track Higlights
Well Characterized Biologics Track Higlights
  • Analytical and Biophysical Characterization Requirements for Novel Modalities
  • Characterization and Biophysical requirements for Vaccine Products in an Expedited Environment 
  • Analytical Techniques, Platforms and Strategies for Cell & Gene Therapies
  • Strategies for Accelerated Method Development/High-Throughput and Rapid Analytical Methods/Phase-Appropriate GMP Work
  • Extended and Functional Characterization
  • Implications of Global Pharmacopeial Monographs on Biosimilar Products
  • Analytical Challenges and Considerations for Formulations and Drug Product
Biological Assays Track Highlights
Biological Assays Track Highlights
  • Improve how to conduct bioassays for complex drugs such as ADCs, Bispecifics and vaccines
  • Assays for later stages of vaccine production to efficiently get your vaccine approved
  • Streamlining assays for gene therapies
  • Critical Reagent Management – keep a high-quality product
  • Get insight from the scientists at the bench
What's New for 2020!
What's New for 2020!
  • Workshop regarding adventitious agent training and TSE filing issues
  • Luncheon Panel Discussion on “What are the challenges when making therapeutics in a COVID-19 setting?”
  • Characterization of vaccines and protein-based therapeutics for COVID-19
  • More speakers and content exploring the unique challenges with analysing cell and gene therapies, including:
    • Streamlining bioassay strategies for MOA
    • Characterization and Comparability
    • Regulatory Requirements
    • Scale up and Manufacturing
  • Additional coverage of the strategies and rapid methods to accelerate development
  • Content on alternate assays beyond traditional assays – insight on improving assays and making them more efficient
  • DoE approaches for bioassays
  • Phase-Appropriate GMP Work
  • Experiences with recently approved therapeutics – Successes, failures and lessons learned
  • New Companies involved this year for the bioassay track include Merck, Sanofi, Zoetis, Janssen

Get the latest event updates

Sign up to get the latest event updates and information.

HERE'S SOME NUMBERS FOR YOU...

$2.5B
Is the cost of a typical drug -- Can you afford to be wasting time?
1/10 DRUGS
That enter Phase 1 reach a patient -- Are you staying up-to-date on the latest regulatory guidelines?
50%
of the top 100 drugs by 2021 will be biologics -- how are you preparing to stay ahead of competition?

CONNECT WITH THE INDUSTRY ANYWHERE IN THE WORLD

Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.   

Our virtual event solutions platform allows you to pre-record or live video stream to engage with visitors, answer live Q&A, provide links to related materials, join instant web conferences, and much more.